The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | Insights into the management and treatment of accelerated/blast-phase MPNs
Anand Patel, MD, University of Chicago Medical Center, Chicago, IL, discusses the management of accelerated/blast-phase myeloproliferative neoplasms (MPN-AP/BP). He notes that there is no standard approach to management, with treatment ranging from intensive chemotherapy to hypomethylating agent (HMA)-based therapy, depending on patient-specific needs. However, overall survival (OS) is still limited, and Dr Patel highlights that the ultimate goal is to achieve disease control, allowing eligible patients to pursue allogeneic transplant (alloSCT). This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
When thinking about management of accelerated and blast-phase MPNs. We know that there’s not a standard approach in terms of what the recommended treatment of these patients are. It can very much be guided by the patient’s fitness, whether ultimately, the goal is to try and get them to an allogeneic stem cell transplant, and what, if any, molecular mutations, their disease may have...
When thinking about management of accelerated and blast-phase MPNs. We know that there’s not a standard approach in terms of what the recommended treatment of these patients are. It can very much be guided by the patient’s fitness, whether ultimately, the goal is to try and get them to an allogeneic stem cell transplant, and what, if any, molecular mutations, their disease may have.
So with that in mind, you know, the treatment regimens that are considered are things ranging from intensive chemotherapy, so AML-like induction regimens, to hypomethylating agent-based therapies, that could be hypomethylating agents with JAK inhibitors, hypomethylating agents with venetoclax or hypomethylating agents with targeted therapies such as IDH inhibitors.
Unfortunately, we know that even, with these various treatment approaches, overall survival is quite limited in this disease and really the goal is to try and achieve disease control and then to be able to pursue an allogeneic transplant in patients who are eligible and looking to kind of move forward with potentially getting a transplant as a potential curative approach.
Read more...
Disclosures
Honoraria:BMS, AbbVie, Sobi; Research funding (institutional): Pfizer, Sumitomo, Kronos Bio.
